Deals and Financings
Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson & Johnson (JNJ) partnered the treatment in a deal that paid Legend $350 million upfront, plus unspecified milestones and royalties. The CAR-T candidate, JNJ-4528, is now in Phase II trials in the US.
Harbour BioMed ((HBM)) raised $75 million in a Series B+ round to advance its clinical-stage compounds